The National Institutes of Health (NIH) is issuing a funding opportunity aimed at advancing institutional training programs for Alzheimer's Disease (AD) and AD-related dementias (ADRD) through the T32 Clinical Trial Not Allowed mechanism. This initiative is designed to build a diverse research workforce capable of leading interdisciplinary efforts in translational research related to AD/ADRD. The program invites applications from higher education institutions to create training that equips predoctoral and postdoctoral researchers with essential skills for conducting rigorous research across various domains, including behavioral science and data analysis. Key dates include an application opening on April 25, 2024, with a maximum project period of five years and an anticipated funding of $2.7 million annually for 3-5 awards. The proposal must emphasize the recruitment of diverse trainees and institutions, include plans for mentorship, and address the NIH's commitment to rigorous research practices. Applications are expected to follow strict guidelines, demonstrating program distinctiveness, a commitment to inclusion, and clear training objectives. This effort aligns with the goals of the National Alzheimer's Project Act which emphasizes team science and data-sharing collaborations to combat the challenges of AD/ADRD effectively.